Selective Repopulation of Normal Mouse Liver by Hepatocytes Transducedin Vivowith Recombinant Adeno-Associated Virus
- 1 January 2001
- journal article
- research article
- Published by Mary Ann Liebert Inc in Human Gene Therapy
- Vol. 12 (1), 45-50
- https://doi.org/10.1089/104303401450951
Abstract
The use of recombinant adeno-associated virus (rAAV) as gene therapy vector for treating liver metabolic diseases is limited by its low transduction efficiency. We describe a strategy for achieving stable and efficient genetic reconstitution in liver after direct administration of rAAV and selective expansion of transduced cells. We have exploited the biology of apoptosis to develop a generic approach for selectively repopulating liver with vector-transduced hepatocytes. Low-level, stable transduction of hepatocytes was achieved by direct injection of rAAV into mouse liver. Expansion of these vector-transduced cells was achieved by incorporating into the construct a minigene expressing Bcl-2 followed by induction of apoptosis in non-vector-containing hepatocytes by systemic administration of a Fas antibody (Ab). Western and Southern blot analysis demonstrated amplification of bcl-2 gene product and viral copy number, respectively, in vector-treated mouse liver when placed under selection. In addition, the percentage of vector transduced cells increased from 2 to 20% after three administrations of Fas Ab, based on immunohistochemical studies.Keywords
This publication has 26 references indexed in Scilit:
- In Vivo Selection of Hepatocytes Transduced with Adeno-Associated Viral VectorsMolecular Therapy, 2000
- Ex VivoHepatic Gene Therapy of a Mouse Model of Hereditary Tyrosinemia Type IHuman Gene Therapy, 1998
- Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectorsNature Genetics, 1997
- Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type INature Genetics, 1996
- Self-induced correction of the genetic defect in tyrosinemia type I.Journal of Clinical Investigation, 1994
- Factors Influencing Retroviral-Mediated Gene Transfer into HepatocytesIn VivoHuman Gene Therapy, 1994
- Lethal effect of the anti-Fas antibody in miceNature, 1993
- Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.Journal of Clinical Investigation, 1993
- Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgeneCell, 1991
- Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activatorCell, 1990